5
Views
2
CrossRef citations to date
0
Altmetric
EMBOLISM PART 2

Pulmonary thromboembolism

2. New trends in prophylaxis and therapy

Pages 81-89 | Published online: 07 Jul 2016

References

  • Brozovic M. Mechanisms of deep venous thrombosis. J R Soc Med 1979;72:602–5
  • Stewart GJ. The role of hypercoagulability in thrombosis. Br J Haematol 1978;40(3):359–62
  • Morris GK, Mitchell JR. Clinical management of venous thromboembolism. Br Med Bull 1978;34:169–75
  • Mitchell JR. Can we really prevent postoperative pulmonary emboli? Br Med J 1979;1:1523–24
  • Kakkar VV. Deep vein thrombosis: detection and prevention. Circulation 1975;51:8–19
  • Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 1959;2:981–9
  • Kakkar VV. International multicentre trial, prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975;2:45–51
  • Kakkar VV. The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J Surg 1978;2:3–18
  • Kiil J, Kiil J, Axelsen F, et al. Prophylaxis against post-operative pulmonary embolism and deep-vein thrombosis by low-dose heparin. Lancet 1978;1:1115–6
  • Williams JW, Eikman EA, Greenberg SH, et al. Failure of low dose heparin to prevent pulmonary embolism after hip surgery or above the knee amputation. Ann Surg 1978;188:468–74
  • Immelman EJ, Jeffrey P, Benatar SR, et al. Failure of low dose heparin to prevent significant thromboembolic complications in high risk surgical patients: interim report of prospective trial. Br Med J 1979;1:1447–50
  • Wessler S, Gitel SN. Low-dose heparin: is the risk worth the benefit? Am Heart J 1979;98:94–101
  • Weiss HJ. Antiplatelet therapy (first of two parts). N Engl J Med 1978;298:1344–7
  • Weiss HJ. Antiplatelet therapy. N Engl J Med 1978;298:1403–6
  • Effect of aspirin on post-operative venous thrombosis: report of the steering committee of a trial sponsored by the medical research council. Lancet 1972;2:441–5
  • Harris WR, Salzman EW, Athanasoulis CA, et al. Aspirin prophylaxis of venous thromboembolis after total hip replacement. N EnglJ Med 1977;297:1246–49
  • Marcus AJ. How useful is antiplatelet therapy? Drug Ther 1979 Oct;9:97–106
  • Moneado S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978;1:1286–89
  • Giudice JC. Pulmonary thromboembolism. In: Johnston R, ed. Pulmonary care. New York: Grune & Stratton, 1973:129–50
  • Rosenberg RD, Rosenberg JS. The anticoagulant function of heparin. Drug Ther 1979 Sep;9:26–38
  • Barrowcliffe TW, Johnson EA, Thomas D. Antithrombin III and heparin. Br Med Bull 1978;34:143–50
  • Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975;292:1046–50
  • Lowe GD, McKillop JH, Prentice AG. Fatal retroperitoneal haemorrhage complicating anticoagulant therapy. Postgrad Med J 1979;55(639):18–21
  • Antithrombin III and heparin. (Editorial) Lancet 1978;1:538–9
  • Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:64–73
  • Saba HI, Saba SR, Blackburn CA, et al. Heparin neutralization of PGI2: effects upon platelets. Science 1979;205:499–501
  • Wessler S, Gitel SN. Rethrombosis—warfarin or low-dose heparin? (Editorial) N Engl J Med 1979;301:889–91
  • Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855–8
  • Bynum LJ, Wilson JE 3d. Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med 1979;67:553–6
  • Urokinase Pulmonary Embolism Trial Study Group. Urokinase pulmonary embolism trial: phase I results. JAMA 1970;214:2163–72
  • Sasahara AA, Ho DD, Sharma GV. When and how to use fibrinolytic agents. Drug Ther 1979 Oct;9:111–28
  • Marder VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979;90:802–8
  • Bell WR, Meek AG. Guidelines for the use of thrombolytic agents. N Engl J Med 1979;301;1266–70
  • Barker WF. David M. Hume memorial lecture: milestones in the use of interruption in venous thromboembolism. Am J Surg 1979;138:192–5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.